Pancreatic enzyme prescription following ivacaftor licensing: A retrospective analysis of the US and UK cystic fibrosis registries.

Rebecca CalthorpeMargaret RosenfeldChristopher H GossNicole GreenMark DerlethSiobhán B CarrAlan SmythIain Stewart

Published in: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society (2024)

Licensing of ivacaftor was followed by a lower prevalence of PERT use in the eligible US population compared to pre-licensing period, as well as lower risk of PERT use in those who received treatment. Inconsistencies in US and UK CF registries were observed.

Keyphrases

cystic fibrosis
pseudomonas aeruginosa
lung function
cross sectional
risk factors
combination therapy